In a phase 1–2 trial, pirtobrutinib demonstrates effectiveness in patients with heavily pretreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have received a covalent BTK inhibitor. The gene discussed is BTK; the disease is B-cell chronic lymphocytic leukemia.